Raj Chovatiya, MD, PhD

10:25 TRuE-V1 and TRuE-V2 studies for the JAK inhibitor ruxolitinib

14:15 Variation in repigmentation with vitiligo

21:00 Data from the long-term extension trial of ruxolitinib

25:75 Achieving meaningful treatment response in vitiligo

30:15 Investigational biomarkers and treatments for vitiligo

Videos

In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.

Achieving Durable Clinical Response with Targeted Treatment for Vitiligo

To watch the video series component of this episode, click here.

Podcasts

Achieving Durable Clinical Response with Targeted Treatments for Vitiligo

1:06 Therapeutic innovations in psoriasis

6:55 Challenges with individualizing treatment

7:51 Selective mechanism of deucravacitinib (TYK2 inhibitor)

11:25 Clinical outcomes of deucravacitinib in psoriasis

15:38 Positioning deucravacitinib in the treatment algorithm

21:41 Novel non-steroidal topicals- tapinarof and roflumilast

26:06 Efficacy and safety of novel topicals

32:13 Benefits of topicals with cross indications

37:08 Summary of novel treatments in psoriasis

In this episode of MEDcast, expert dermatologists discuss exciting advancements in systemic therapies such as JAK inhibitors, and the latest breakthroughs in topical treatments for plaque psoriasis

Novel Systemic and Topical Treatment for Plaque Psoriasis

In this episode of MEDcast, expert dermatologists discuss exciting advancements in systemic therapies such as JAK inhibitors, and the latest breakthroughs in topical treatments for plaque psoriasis.

Raj Chovatiya, MD, PhD

Articles